Mean performance of patients and controls for each measurement of the COMT Val158Met genotype.

<p>Data indicate means±SD.</p><p>COMT, catechol-O-methyltransferase; BACS-J, Brief Assessment of Cognition in Schizophrenia, Japanese-language version; SNP, single nucleotide polymorphism.</p

Factors that influenced scores of the BACS-J measuremnts and the composite scores of multiple regression analysis.

<p>COMT, catechol-O-methyltransferase; BACS-J, Brief Assessment of Cognition in Schizophrenia, Japanese-language version.</p

Multiple regression analysis of the improvement in MADRS at week 6.

<p>PXT: paroxetine, *: p<0.05.</p

Subject demographics.

a<p>: Fisher's exact test;</p>b<p>: Chi-squared test.</p

The relationship between paroxetine plasma concentration and the MADRS improvement rate: The data from each subject are plotted.

<p>The relationship between paroxetine plasma concentration and the MADRS improvement rate: The data from each subject are plotted.</p

Impact of the <i>Superoxide Dismutase 2</i> Val16Ala Polymorphism on the Relationship between Valproic Acid Exposure and Elevation of γ-Glutamyltransferase in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

<div><p>Background</p><p>There has been accumulating evidence that there are associations among γ-glutamyltransferase (γ-GT) elevation and all-cause mortality, cardiovascular diseases and metabolic diseases, including nonalcoholic fatty liver disease. The primary objective of this study was to evaluate the impact of the most common and potentially functional polymorphisms of antioxidant enzyme genes, i.e. <i>superoxide dismutase 2 (SOD2)</i>, <i>glutathione S-transferase M1</i> and <i>glutathione S-transferase T1</i>, on the γ-GT elevation during valproic acid (VPA) therapy.</p><p>Methods and Findings</p><p>This retrospective study included 237 and 169 VPA-treated Japanese patients with epilepsy for population pharmacokinetic and pharmacokinetic-pharmacodynamic analyses, respectively. A nonlinear mixed-effect model represented the pharmacokinetics of VPA and the relationships between VPA exposure and γ-GT elevation. A one-compartment model of the pharmacokinetic parameters of VPA adequately described the data; while the model for the probability of the γ-GT elevation was fitted using a logistic regression model, in which the logit function of the probability was a linear function of VPA exposure. The <i>SOD2</i> Val16Ala polymorphism and complication with intellectual disability were found to be significant covariates influencing the intercept of the logit function for the probability of an elevated γ-GT level. The predicted mean percentages of the subjects with γ-GT elevation were about 2- to 3-fold, 3- to 4-fold and 4- to 8-fold greater in patients with the <i>SOD2</i> Val/Val genotype but without any intellectual disability, those with the <i>SOD2</i> Val/Ala or Ala/Ala genotype and intellectual disability and those with the <i>SOD2</i> Val/Val genotype and intellectual disability, respectively, compared to those with the <i>SOD2</i> Val/Ala or Ala/Ala genotype without intellectual disability.</p><p>Conclusion</p><p>Our results showed that the <i>SOD2</i> Val16Ala polymorphism has an impact on the relationship between VPA exposure and γ-GT elevation in patients with epilepsy. These results suggest that determining the <i>SOD2</i> genotype could be helpful for preventing the VPA-induced γ-GT elevation.</p></div

The predicted mean percentages of the subjects with γ-GT elevation and the mean odds ratios (95% CIs) for γ-GT elevation during VPA therapy according to the <i>SOD2</i> Val16Ala genotype and complication with intellectual disability when different daily doses of VPA were administered to patients without any co-treatment.

<p>γ-GT: γ-glutamyltransferase; VPA = valproic acid; Dose = daily dose of VPA; SOD2 = superoxide dismutase 2; CIs = confidence intervals; − = absent; + = present.</p><p>The predicted mean percentages of the subjects with γ-GT elevation and the mean odds ratios (95% CIs) for γ-GT elevation during VPA therapy according to the <i>SOD2</i> Val16Ala genotype and complication with intellectual disability when different daily doses of VPA were administered to patients without any co-treatment.</p

The median values of the PD parameter estimates of VPA in the final population PK-PD models obtained using the NONMEM program and the bootstrap analysis.

<p>VPA = valproic acid; PD = pharmacodynamic; PK = pharmacokinetic; NONMEM = nonlinear mixed-effect model; RES = relative standard error; CIs = confidence intervals; Dose = daily dose of VPA; BASE = intercept; SLOPE = slope relating the AUC of VPA; SOD2 = superoxide dismutase 2; ω = coefficient of variation of inter-individual variability; logit (Pr) = logit function of probability of having an elevated γ-GT level.</p><p>The median values of the PD parameter estimates of VPA in the final population PK-PD models obtained using the NONMEM program and the bootstrap analysis.</p

A summary of the patient characteristics.

<p>PK = pharmacokinetic; PD = pharmacodynamic; N = number; SD = standard deviation; VPA = valproic acid; γ-GT: γ-glutamyltransferase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN = blood urea nitrogen; CBZ = carbamazepine; CLB = clobazam; GBP = gabapentine; PB = phenobarbital; PHT = phenytoin; TPM = topiramate; ZNS = zonisamide.</p><p>A summary of the patient characteristics.</p

The relationships evaluated in the framework for the γ-GT elevation during VPA therapy.

<p>The solid lines indicate the relationships included in the final population PK and PK-PD models. Black letters indicate relationships included in the final models, and grey letters indicate relationships investigated, but not included, in the final models. PK = pharmacokinetic; PD = pharmacodynamics; VPA = valproic acid γ-GT: γ-glutamyltransferase.</p